Colon-specific drug delivery systems based on cyclodextrin prodrugs: In vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates

doi:10.3748/wjg.v11.i47.7457

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 47

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2466)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

223

HTML

2026

Figures (1-1)

113

Tables (1-3)

104

Sum=2466

Dec 21, 2005 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (21)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Research

World J Gastroenterol. Dec 21, 2005; 11(47): 7457-7460
Published online Dec 21, 2005. doi: 10.3748/wjg.v11.i47.7457

Table 1 Recovery (%) of α-CyD-5-ASA, 5-ASA and Ac-5-ASA in the GIT, plasma, urine, feces, and liver after oral administration of α-CyD-5-ASA to rats (mean±SD)

Time	Stomach			Small intestine			Cecum			Colon
(h)	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA
4	19.8±4.8	0.0±0.0	0.0±0.0	41.6±30.8	0.0±0.0	0.0±0.0	7.7±7.6	14.7±17.3	7.3±12.6	6.3±11.0	0.8±1.0	1.8±1.6
8	2.8±4.3	0.0±0.0	0.0±0.0	14.3±6.5	0.7±0.4	0.0±0.0	11.3±14.0	20.2±22.4	6.1±5.8	7.2±9.9	9.1±7.7	18.4±13.6
12	0.0±0.0	0.1±0.1	0.4±0.5	1.7±0.4	0.5±0.7	2.5±3.9	9.4±11.8	4.7±7.4	6.2±6.4	17.2±24.0	17.3±23.7	16.6±17.9
24	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	22.8±24.2	9.2±9.0	0.3±0.5	7.9±13.6	13.3±15.6	1.4±1.1	23.4±15.6
	Plasma			Urine			Feces			Liver			Total
	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	recovery
4	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	69.3±29.0
8	0.0±0.0	0.5±0.3	4.0±2.6	0.0±0.0	0.2±0.1	2.0±1.3	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.3±0.1	3.0±2.2	65.0±11.9
12	0.0±0.0	0.4±0.5	4.7±4.0	0.0±0.0	0.3±0.4	2.8±2.4	0.3±0.5	7.1±8.2	7.1±8.0	0.0±0.0	0.2±0.3	0.4±0.8	50.5±20.0
24	0.0±0.0	1.4±1.2	1.9±1.9	0.0±0.0	0.0±0.0	0.0±0.0	4.3±7.4	1.3±1.3	9.3±11.8	0.0±0.0	1.4±1.3	2.1±2.5	12.6±7.6

Total recovery=100×(amount of the intact prodrugs, 5-ASA and Ac-5-ASA recovered from stomach, small intestine, cecum, colon, blood, urine, liver, and feces)/dose.

Table 2 Recovery (%) of β-CyD-5-ASA, 5-ASA, and Ac-5-ASA in GIT, plasma, urine, feces, and liver after oral administration of 9 9 β-CyD-5-ASA to rats (mean±SD)

Time	Stomach			Small intestine			Cecum			Colon
(h)	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA
4	26.7±3.2	0.0±0.0	0.0±0.0	47.0±27.6	0.0±0.0	0.0±0.0	13.2±13.7	1.0±0.6	0.3±0.3	9.7±16.9	1.2±1.4	0.9±1.4
8	8.5±12.9	0.0±0.0	0.0±0.0	14.9±6.6	2.4±3.4	0.0±0.0	30.6±35.8	7.5±11.6	3.8±3.8	12.3±17.0	9.1±4.4	4.3±2.9
12	0.0±0.0	0.0±0.0	0.7±1.2	6.6±7.9	0.4±0.3	3.0±0.8	8.4±7.4	18.7±13.1	11.7±12.8	16.1±12.6	13.5±12.4	7.9±7.3
24	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	2.9±4.4	16.6±16.1	10.3±16.7	17.4±15.2	27.2±45.2	11.0±12.9	5.3±5.9
	Plasma			Urine			Feces			Liver			Total
	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	recovery
4	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	64.0±14.3
8	0.0±0.0	0.7±0.7	2.4±3.0	0.0±0.0	0.1±0.0	0.4±0.4	0.0±0.0	0.1±0.0	0.1±0.1	0.0±0.0	1.9±2.5	1.1±1.6	40.6±14.7
12	0.0±0.0	1.2±0.5	4.1±4.6	0.0±0.0	2.4±3.5	2.3±2.2	0.3±0.9	0.0±0.0	1.1±1.8	0.0±0.0	0.5±0.7	0.8±1.2	35.6±10.7
24	0.0±0.0	2.3±2.6	1.7±2.2	0.0±0.0	0.0±0.0	0.0±0.0	4.6±7.9	0.2±0.2	0.7±0.9	0.0±0.0	0.0±0.0	0.0±0.0	14.8±6.5

Total recovery=100×(amount of the intact prodrugs, 5-ASA, and Ac-5-ASA recovered from stomach, small intestine, cecum, colon, blood, urine, liver, and feces)/dose.

Table 3 Recovery (%) of γ-CyD-5-ASA, 5-ASA, and Ac-5-ASA in GIT, plasma, urine, feces, and liver after oral administration of γ-CyD-5-ASA to rats (mean±SD)

Time	Stomach			Small intestine			Cecum			Colon
(h)	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA
4	19.8±9.4	0.0±0.0	0.0±0.0	46.4±28.7	0.2±0.3	0.0±0.0	10.0±10.1	0.9±0.3	5.4±4.8	8.4±14.6	6.4±5.4	2.2±1.8
8	3.2±5.0	0.0±0.0	0.0±0.0	16.2±3.3	2.4±1.5	0.0±0.0	18.2±24.8	15.7±9.4	2.2±2.7	4.0±4.2	20.2±8.2	7.7±4.2
12	0.0±0.0	0.2±0.0	0.6±0.6	2.1±1.2	0.8±0.3	0.0±0.0	7.6±7.0	4.9±2.5	14.1±12.2	7.9±5.2	7.2±1.5	34.6±20.8
24	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.8±0.7	5.3±5.8	2.1±1.8	40.5±35.4	15.0±22.3	19.4±15.6	5.1±4.0
	Plasma			Urine			Feces			Liver			Total
	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	Prodrug	5-ASA	AC-5-ASA	recovery
4	0.0±0.0	0.0±0.0	0.2±0.2	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	76.8±12.2
8	0.0±0.0	0.2±0.1	2.5±2.4	0.0±0.0	1.1±0.2	1.8±1.8	0.0±0.0	0.0±0.0	0.0±0.0	0.0±0.0	2.9±2.2	1.7±1.8	61.9±22.0
12	0.0±0.0	1.8±1.7	3.8±3.5	0.0±0.0	0.1±0.0	6.4±6.6	0.5±0.8	2.2±0.8	0.0±0.0	0.0±0.0	0.9±0.6	4.3±0.2	48.5±6.8
24	0.0±0.0	1.3±1.4	0.6±0.1	0.0±0.0	0.1±0.0	2.5±2.4	3.7±4.1	0.3±0.0	3.4±1.3	0.0±0.0	0.0±0.0	0.0±0.0	17.2±2.4

Total recovery=100×(amount of the intact prodrugs, 5-ASA, and Ac-5-ASA recovered from stomach, small intestine, cecum, colon, blood, urine, liver, and feces)/dose.

Citation: Zou MJ, Cheng G, Okamoto H, Hao XH, An F, Cui FD, Danjo K. Colon-specific drug delivery systems based on cyclodextrin prodrugs: In vivo evaluation of 5-aminosalicylic acid from its cyclodextrin conjugates. World J Gastroenterol 2005; 11(47): 7457-7460
URL: https://www.wjgnet.com/1007-9327/full/v11/i47/7457.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i47.7457